RPRX

Royalty Pharma
D

RPRX

Arincen67/100B

Royalty Pharma balance sheet 2015–2026

Royalty Pharma had 544.86M USD in cash and short-term investments on 30 September 2026, against total debt of 8.59B USD: net debt of 8.04B USD.

Total assets Total liabilities Shareholders' equity

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
Latest
Q3 FY2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
Cash and equivalents
513.66M618.70M929.03M477.01M1.71B1.54B1.01B246.20M1.92B1.38B1.67B
Short-term investments
31.20M18.80M841.97M756.74M717.04M1.26B1.64B547.02M461.82M0.000.00
544.86M637.50M1.77B1.23B2.43B2.80B2.65B793.21M2.39B1.38B1.67B
Cash growth
-42.95%-64.00%+43.55%-49.18%-13.39%+5.82%+233.97%-66.76%+72.70%-17.48%-2.71%
Receivables
972.81M883.70M26.96M22.41M36.60M68.31M39.17M38.77M198.63M0.000.00
Inventory
0.000.000.000.000.000.000.000.000.000.000.00
Other current assets
7.90M-902.20M4.19M18.04M90.52M6.63M8.60M92.00K23.90M1.57B1.33B
Total current assets
1.53B619.00M1.80B1.27B2.55B2.88B2.70B832.07M2.61B2.95B3.00B
Property, plant and equipment
0.000.000.000.000.000.000.000.000.000.000.00
Long-term investments
808.61M171.31M16.39B15.10B14.23B14.63B13.28B11.48B8.67B0.000.00
Goodwill and intangibles
923.54M924.63M15.13B——5.67M28.67M51.72M75.65M——
Goodwill
923.54M924.63M—————————
Intangible assets
——15.13B——5.67M28.67M51.72M75.65M——
Other non-current assets
16.20B15.97B-15.09B6.52M29.63M4.15M10.00M87.95M19.11M0.000.00
Total assets
19.46B19.62B18.22B16.38B16.81B17.52B16.02B12.45B11.37B11.37B10.48B
Accounts payable
31.42M19.40M13.37M15.17M7.91M5.62M10.78M11.18M4.48M0.000.00
Deferred revenue
0.000.000.000.000.000.000.000.000.000.000.00
Short-term debt
996.97M380.00M997.77M0.00997.51M0.000.00281.98M281.44M280.93M172.68M
Other current liabilities
59.86M163.98M68.60M11.38M12.40M0.0018.60M9.22M0.00102.49M124.63M
Total current liabilities
1.18B636.21M1.25B161.38M1.17B171.25M307.89M333.42M580.17M383.41M297.32M
Long-term debt
7.59B8.57B6.61B6.14B6.12B7.10B5.82B5.96B6.24B6.52B5.72B
Other non-current liabilities
896.43M682.61M12.08M900.00K2.50M0.000.0018.90M0.000.000.00
Lease obligations, current
0.000.000.000.000.000.000.000.000.000.000.00
Lease obligations, long-term
0.0016.10M0.000.000.000.000.000.000.000.000.00
Total liabilities
9.67B9.91B7.88B6.30B7.29B7.27B6.12B6.31B6.82B6.90B6.02B
Common stock and paid-in capital
45.00K106.00K108.00K108.00K107.00K106.00K102.00K3.28B3.28B0.000.00
Retained earnings
2.50B2.36B2.85B2.52B1.96B2.26B1.92B2.83B1.22B0.000.00
Accumulated other comprehensive income
0.000.000.000.000.0016.49M34.40M2.09M-10.26M0.000.00
Shareholders' equity
6.84B6.48B6.95B6.53B5.63B5.78B4.82B6.11B4.49B4.46B4.45B
Minority interest
2.96B3.24B3.40B3.56B3.90B4.47B5.08B35.88M63.87M0.000.00
8.59B8.95B7.61B6.14B7.12B7.10B5.82B6.24B6.52B6.80B5.90B
Net cash
-8.04B-8.31B-5.84B-4.90B-4.69B-4.29B-3.17B-5.44B-4.13B-5.42B-4.22B
Working capital
346.56M-17.21M548.52M1.11B1.39B2.71B2.39B498.66M2.03B2.56B2.71B
Book value per share
12.2811.5711.6910.839.9613.9312.4217.2412.6712.597.32
Tangible book value
5.91B5.55B-8.18B6.53B5.63B5.77B4.79B6.05B4.41B4.46B4.45B
Tangible book value per share
10.629.92-13.7710.839.9613.9112.3417.0912.4612.597.32
Current ratio
1.290.971.447.902.1916.818.762.504.507.6910.10
Debt to equity
1.261.381.100.941.261.231.211.021.451.521.33

Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.

Common questions about Royalty Pharma's cash and debt

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.